Cancer specialist Tessera Diagnostics raises $3 million:
This article was originally published in Clinica
Tessera Diagnostics, a Seattle, Washington-based start-up focusing on cancer, has raised $3.2m in a series A financing round, exceeding its target of $1.75m. Following the initial closing of the round last April, the company started a funded research programme at the University of Pittsburgh. Originally it had access to prostate specific cancer markers; it has now gained an option on colon cancer markers from the university. Tessera is developing highly specific early-stage cancer diagnostics, and is seeking partners for other applications of its markers in imaging, therapeutics and drug discovery. It was founded by president and CEO Robert Masterson and chairman Raymond Cairncross.